One hundred and seventy-five patients with atrial fibrillation treated for the first time with DC shock were divided into two groups according to year of birth. Group I received a long-acting quinidine bisulphate preparation, the dosage of which was adjusted to give serum levels of 1-3 mg./l. Side-effects were rare with this dosage. The lack of controlled data on the value of prophylactic quinidine prompted the present study.
1967; Hall and Wood, I968) .
The lack of controlled data on the value of prophylactic quinidine prompted the present study.
Subjects and methods
Our study comprised all the patients of three departments of medicine of the University Central Hospital, Helsinki, who were referred for the first time for electric conversion of their atrial fibrillaReceived I6 June I969. 1 Supported by a grant of the Sigrid Juselius Foundation, Helsinki, Finland. tion to the cardiovascular laboratory between May I967 and June 1968. During this time cardioversion was attempted for the first time in 207 patients with atrial fibrillation. For various reasons, to be discussed later, 32 patients were discarded from the study, thus leaving 175 patients for final analysis. The patients were divided into two groups: those bom in odd years formed the quinidine group, those bom in even years formed the control group with no quinidine. Quinidine treatment was started 2 tO 5 days before attempted conversion. A long-acting quinidine bisulphate preparation (Kinidin-Duretter ®, Hassle) was used and the dosage was adjusted to give serum levels of I-3 mg./l. (Cramer and Isaksson, I963) . This was achieved in most cases with doses ranging from o-2 to o-6 g. twice a day, the usual dose being o04 g. twice a day. Otherwise the treatment of both groups was the same. Most patients were on digitalis, which was interrupted 36 hours before shock therapy. About one-third of the patients were on anticoagulant therapy. Cardioversion was performed with a synchronized DC defibrillator (Electrodyne) under thiopentone anaesthesia with o05 mg. atropine sulphate as premedication. A shock of Ioo watts was given and, if necessary, additional shocks of 200 and 300 watts. If sinus rhythm was restored, quinidine treatment was continued in the quinidine group. The patients of the control group were left without quinidine. If cardioversion was unsuccessful (primary failures) or if atrial fibrillation recurred during the stay in hospital (secondary failures), the patient was submitted to a cross-over experiment. This means that a second attempt was made as follows: patients of the control group received quinidine and those belonging to the quinidine group were given none. If the second trial was successful, quinidine medication was continued in this new quinidine group. The patients were either seen at regular intervals at the out-patient departments or they sent an electrocardiogram after three months with a report on the drugs they had used.
Results
Of the I75 patients of the present study, 88 were born in odd years and received quinidine and 87 were born in even years and received no quinidine. Details of both groups are given in Tables I and 2. In the quinidine group sinus rhythm was restored in 7 patients after starting the usual prophylactic quinidine therapy, making electric conversion unnecessary. Restoration of sinus rhythm occurred in one patient of the control group during digitalization. These patients were not excluded from the respective groups. Fig. I shows the success rate of conversion in both groups, and the percentages ofpatients in sinus rhythm when leaving hospital and after three months. The difference in favour of the quinidine group after three months is statistically highly significant (p < o-ooi).
The results of the cross-over experiment of primary and secondary failures are shown in Fig. 2 and 3 . It should be pointed out that amnong the failures in the control group there was one patient in whom sinus rhythm was restored after starting quinidine therapy in prophylactic dosage, and there were two further patients among the secondary failures. All three patients maintained sinus rhythm during the observation period.
FIG. 2 Effect of quinidine on the maintenance of sinus rhythm in cross-over experiment on primary failures. The upper parts of the first columns represent patients in whom no second attempt was made to restore sinus rhythm. by electric shock. The serum quinidine concentration at this time was 2a2 mg./l., and further quinidine was withheld. During the following hours he had atrial fibrillation with multiple ventricular extrasystoles and received procainamide and lignocaine. Later, because of the rapid ventricular rate, he was given digitalis. Hereafter, bouts of ventricular tachycardia appeared which could not be controlled in spite of intensive therapy including multiple electric shocks, drugs such as lignocaine and propranolol, and transvenous artificial pacing. The patient died i9 hours after his first attack of ventricular tachycardia and 30 hours after the last dose of quinidine.
Discussion
The results of this study show a sinus rhythm maintaining effect of quinidine after restoration of sinus rhythm in patients with atrial fibrillation.
The grouping of the patients according to year of birth resulted in comparability in respect of age, sex, and duration ofatrial fibrillation. There were, however, more patients who had been operated on for mitral stenosis in the quinidine group than in the control group (Table I) . Analysis of these patients showed that, after commissurotomy, patients on quinidine or without quinidine had the same success rate as the group they belonged to. Thus, the unequal distribution of operated patients did not influence the results.
In spite of the small number of patients, the results of the cross-over experiment are impressive. In this part of the study where every patient was his own control the value of quinidine was evident.
The use of ordinary quinidine sulphate tablets, or lack of control of serum quinidine concentration, or small numbers of patients may explain the negative results obtained by others (Oram and Davies, I964; Halmos, I966; Engstrom, I967; Hall and Wood, I968; Radford and Evans, I968) . Fluctuations of the serum quinidine concentration are relatively small with the long-acting quinidine preparation used in this study (Cramer, Varnauskas, and Werko, I963) , and the twice daily dosage scheme is easy for the patient to carry out.
After exclusion of the 4 patients with primary quinidine intolerance, no side-effects were observed in this study. The role of quinidine in the death of one patient remains unsolved, but seems improbable as the death occurred 30 hours after the last quinidine dose.
We consider the rarity of quinidine sideeffects to be partly due to the fact that a long-acting quinidine preparation was used whereby the high peak values obtained with ordinary quinidine sulphate preparations were avoided (Cramer et al., I963; Cullhed, Hamfelt, and Malers, I966). Second, a low dosage regimen was used with individual adjustment of the quinidine dose according to serum quinidine values. This is an important point, since, though serum quinidine concentrations in a given patient are fairly constant, there is a remarkable variation in the serum levels obtained in different patients with equal doses (Cramer, I968).
As is generally known, a considerable number of patients remain in sinus rhythm after DC shock therapy of atrial fibrillation without any antiarrhythmic drugs. This also occurred in the present series. We think, therefore, that the first attempt to restore sinus rhythm should be performed without any antiarrhythmic drug prophylaxis. If there is a failure to restore sinus rhythm or an early recurrence of atrial fibrillation, a second attempt with prophylactic quinidine treatment in low doses and adjusted according to serum quinidine levels, is indicated. Thus, a significant number of additional patients can be maintained in sinus rhythm. However, for each patient it needs to be considered whether the advantages of sinus rhythm outweigh the disadvantages of long-term drug therapy. 
